APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Complicated Skin and Skin Structure Infections Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Complicated Skin and Skin Structure Infections Drugs Industry Research Report 2026

Report ID 17427898014 July 2026125 pages

Choose your research edition.

Industry ResearchComplicated Skin and Skin Structure Infections Drugs Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Complicated Skin and Skin Structure Infections Drugs Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Complicated Skin and Skin Structure Infections Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Complicated Skin and Skin Structure Infections Drugs Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Complicated Skin and Skin Structure Infections Drugs Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

The global Complicated Skin and Skin Structure Infections Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Complicated Skin and Skin Structure Infections Drugs is forecast to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Complicated Skin and Skin Structure Infections Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Complicated Skin and Skin Structure Infections Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Complicated Skin and Skin Structure Infections Drugs include , among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Complicated Skin and Skin Structure Infections Drugs market in revenue (US$ million) and, where applicable, sales volume (t), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of types and applications, harmonizes vendor attribution, and presents comparable time series by company, type, application, and region/country, including indicative price bands (US$/t) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for manufacturers, new entrants, channel partners, and investors; the report also reviews technology shifts and notable product introductions relevant to Complicated Skin and Skin Structure Infections Drugs.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Complicated Skin and Skin Structure Infections Drugs Market by Company

Abbott

Cipla Inc

Dr Reddy's Laboratories Ltd

Endo International Inc

F. Hoffmann-La Roche Ltd

Glenmark Pharmaceuticals Ltd

Lupin

Melinta Therapeutics, Inc

MerLion Pharmaceuticals GmbH

Novartis AG

Paratek Pharmaceuticals, Inc

Pfizer Inc

Teva Pharmaceutical Industries Ltd

Zydus Group

Complicated Skin and Skin Structure Infections Drugs Segment by Type

Vancomycin

Ceftaroline

Tedizolid

Tedizolid

Linezolid

Darbavansing

Olivanstar

Complicated Skin and Skin Structure Infections Drugs Segment by Application

Specialist Clinic

Hospital

Home Care

Other

Complicated Skin and Skin Structure Infections Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Complicated Skin and Skin Structure Infections Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Complicated Skin and Skin Structure Infections Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Complicated Skin and Skin Structure Infections Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Complicated Skin and Skin Structure Infections Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Complicated Skin and Skin Structure Infections Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Complicated Skin and Skin Structure Infections Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Complicated Skin and Skin Structure Infections Drugs Production by Manufacturers (t) & (2021-2026) Table 6. Global Complicated Skin and Skin Structure Infections Drugs Production Market Share by Manufacturers Table 7. Global Complicated Skin and Skin Structure Infections Drugs Production Value by Manufacturers (US$ Million) & (2021-2026) Table 8. Global Complicated Skin and Skin Structure Infections Drugs Production Value Market Share by Manufacturers (2021-2026) Table 9. Global Complicated Skin and Skin Structure Infections Drugs Average Price (USD/t) of Manufacturers (2021-2026) Table 10. Global Complicated Skin and Skin Structure Infections Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Complicated Skin and Skin Structure Infections Drugs Key Manufacturers, Manufacturing Sites & Headquarters Table 12. Global Complicated Skin and Skin Structure Infections Drugs Manufacturers, Product Type & Application Table 13. Global Complicated Skin and Skin Structure Infections Drugs Manufacturers Established Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Complicated Skin and Skin Structure Infections Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Production Value of 2025) Table 16. Manufacturers Mergers & Acquisitions, Expansion Plans Table 17. Abbott Company Information Table 18. Abbott Business Overview Table 19. Abbott Complicated Skin and Skin Structure Infections Drugs Production (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 20. Abbott Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 21. Abbott Recent Development Table 22. Cipla Inc Company Information Table 23. Cipla Inc Business Overview Table 24. Cipla Inc Complicated Skin and Skin Structure Infections Drugs Production (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 25. Cipla Inc Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 26. Cipla Inc Recent Development Table 27. Dr Reddy's Laboratories Ltd Company Information Table 28. Dr Reddy's Laboratories Ltd Business Overview Table 29. Dr Reddy's Laboratories Ltd Complicated Skin and Skin Structure Infections Drugs Production (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 30. Dr Reddy's Laboratories Ltd Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 31. Dr Reddy's Laboratories Ltd Recent Development Table 32. Endo International Inc Company Information Table 33. Endo International Inc Business Overview Table 34. Endo International Inc Complicated Skin and Skin Structure Infections Drugs Production (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 35. Endo International Inc Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 36. Endo International Inc Recent Development Table 37. F. Hoffmann-La Roche Ltd Company Information Table 38. F. Hoffmann-La Roche Ltd Business Overview Table 39. F. Hoffmann-La Roche Ltd Complicated Skin and Skin Structure Infections Drugs Production (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 40. F. Hoffmann-La Roche Ltd Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 41. F. Hoffmann-La Roche Ltd Recent Development Table 42. Glenmark Pharmaceuticals Ltd Company Information Table 43. Glenmark Pharmaceuticals Ltd Business Overview Table 44. Glenmark Pharmaceuticals Ltd Complicated Skin and Skin Structure Infections Drugs Production (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 45. Glenmark Pharmaceuticals Ltd Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 46. Glenmark Pharmaceuticals Ltd Recent Development Table 47. Lupin Company Information Table 48. Lupin Business Overview Table 49. Lupin Complicated Skin and Skin Structure Infections Drugs Production (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 50. Lupin Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 51. Lupin Recent Development Table 52. Melinta Therapeutics, Inc Company Information Table 53. Melinta Therapeutics, Inc Business Overview Table 54. Melinta Therapeutics, Inc Complicated Skin and Skin Structure Infections Drugs Production (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 55. Melinta Therapeutics, Inc Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 56. Melinta Therapeutics, Inc Recent Development Table 57. MerLion Pharmaceuticals GmbH Company Information Table 58. MerLion Pharmaceuticals GmbH Business Overview Table 59. MerLion Pharmaceuticals GmbH Complicated Skin and Skin Structure Infections Drugs Production (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 60. MerLion Pharmaceuticals GmbH Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 61. MerLion Pharmaceuticals GmbH Recent Development Table 62. Novartis AG Company Information Table 63. Novartis AG Business Overview Table 64. Novartis AG Complicated Skin and Skin Structure Infections Drugs Production (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 65. Novartis AG Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 66. Novartis AG Recent Development Table 67. Paratek Pharmaceuticals, Inc Company Information Table 68. Paratek Pharmaceuticals, Inc Business Overview Table 69. Paratek Pharmaceuticals, Inc Complicated Skin and Skin Structure Infections Drugs Production (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 70. Paratek Pharmaceuticals, Inc Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 71. Paratek Pharmaceuticals, Inc Recent Development Table 72. Pfizer Inc Company Information Table 73. Pfizer Inc Business Overview Table 74. Pfizer Inc Complicated Skin and Skin Structure Infections Drugs Production (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 75. Pfizer Inc Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 76. Pfizer Inc Recent Development Table 77. Teva Pharmaceutical Industries Ltd Company Information Table 78. Teva Pharmaceutical Industries Ltd Business Overview Table 79. Teva Pharmaceutical Industries Ltd Complicated Skin and Skin Structure Infections Drugs Production (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 80. Teva Pharmaceutical Industries Ltd Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 81. Teva Pharmaceutical Industries Ltd Recent Development Table 82. Zydus Group Company Information Table 83. Zydus Group Business Overview Table 84. Zydus Group Complicated Skin and Skin Structure Infections Drugs Production (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 85. Zydus Group Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 86. Zydus Group Recent Development Table 87. Global Complicated Skin and Skin Structure Infections Drugs Production Comparison by Region: 2021 VS 2025 VS 2032 (t) Table 88. Global Complicated Skin and Skin Structure Infections Drugs Production by Region (2021-2026) & (t) Table 89. Global Complicated Skin and Skin Structure Infections Drugs Production Market Share by Region (2021-2026) Table 90. Global Complicated Skin and Skin Structure Infections Drugs Production Forecast by Region (2027-2032) & (t) Table 91. Global Complicated Skin and Skin Structure Infections Drugs Production Market Share Forecast by Region (2027-2032) Table 92. Global Complicated Skin and Skin Structure Infections Drugs Production Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 93. Global Complicated Skin and Skin Structure Infections Drugs Production Value by Region (2021-2026) & (US$ Million) Table 94. Global Complicated Skin and Skin Structure Infections Drugs Production Value Market Share by Region (2021-2026) Table 95. Global Complicated Skin and Skin Structure Infections Drugs Production Value Forecast by Region (2027-2032) & (US$ Million) Table 96. Global Complicated Skin and Skin Structure Infections Drugs Market Average Price (USD/t) by Region (2021-2026) Table 97. Global Complicated Skin and Skin Structure Infections Drugs Market Average Price (USD/t) by Region (2027-2032) Table 98. Global Complicated Skin and Skin Structure Infections Drugs Consumption Comparison by Region: 2021 VS 2025 VS 2032 (t) Table 99. Global Complicated Skin and Skin Structure Infections Drugs Consumption by Region (2021-2026) & (t) Table 100. Global Complicated Skin and Skin Structure Infections Drugs Consumption Market Share by Region (2021-2026) Table 101. Global Complicated Skin and Skin Structure Infections Drugs Forecasted Consumption by Region (2027-2032) & (t) Table 102. Global Complicated Skin and Skin Structure Infections Drugs Forecasted Consumption Market Share by Region (2027-2032) Table 103. North America Complicated Skin and Skin Structure Infections Drugs Consumption Growth Rate by Country: 2021 VS 2025 VS 2032 (t) Table 104. North America Complicated Skin and Skin Structure Infections Drugs Consumption by Country (2021-2026) & (t) Table 105. North America Complicated Skin and Skin Structure Infections Drugs Consumption by Country (2027-2032) & (t) Table 106. Europe Complicated Skin and Skin Structure Infections Drugs Consumption Growth Rate by Country: 2021 VS 2025 VS 2032 (t) Table 107. Europe Complicated Skin and Skin Structure Infections Drugs Consumption by Country (2021-2026) & (t) Table 108. Europe Complicated Skin and Skin Structure Infections Drugs Consumption by Country (2027-2032) & (t) Table 109. Asia Pacific Complicated Skin and Skin Structure Infections Drugs Consumption Growth Rate by Country: 2021 VS 2025 VS 2032 (t) Table 110. Asia Pacific Complicated Skin and Skin Structure Infections Drugs Consumption by Country (2021-2026) & (t) Table 111. Asia Pacific Complicated Skin and Skin Structure Infections Drugs Consumption by Country (2027-2032) & (t) Table 112. South America, Middle East & Africa Complicated Skin and Skin Structure Infections Drugs Consumption Growth Rate by Country: 2021 VS 2025 VS 2032 (t) Table 113. South America, Middle East & Africa Complicated Skin and Skin Structure Infections Drugs Consumption by Country (2021-2026) & (t) Table 114. South America, Middle East & Africa Complicated Skin and Skin Structure Infections Drugs Consumption by Country (2027-2032) & (t) Table 115. Global Complicated Skin and Skin Structure Infections Drugs Production by Type (2021-2026) & (t) Table 116. Global Complicated Skin and Skin Structure Infections Drugs Production by Type (2027-2032) & (t) Table 117. Global Complicated Skin and Skin Structure Infections Drugs Production Market Share by Type (2021-2026) Table 118. Global Complicated Skin and Skin Structure Infections Drugs Production Market Share by Type (2027-2032) Table 119. Global Complicated Skin and Skin Structure Infections Drugs Production Value by Type (2021-2026) & (US$ Million) Table 120. Global Complicated Skin and Skin Structure Infections Drugs Production Value by Type (2027-2032) & (US$ Million) Table 121. Global Complicated Skin and Skin Structure Infections Drugs Production Value Market Share by Type (2021-2026) Table 122. Global Complicated Skin and Skin Structure Infections Drugs Production Value Market Share by Type (2027-2032) Table 123. Global Complicated Skin and Skin Structure Infections Drugs Price by Type (2021-2026) & (USD/t) Table 124. Global Complicated Skin and Skin Structure Infections Drugs Price by Type (2027-2032) & (USD/t) Table 125. Global Complicated Skin and Skin Structure Infections Drugs Production by Application (2021-2026) & (t) Table 126. Global Complicated Skin and Skin Structure Infections Drugs Production by Application (2027-2032) & (t) Table 127. Global Complicated Skin and Skin Structure Infections Drugs Production Market Share by Application (2021-2026) Table 128. Global Complicated Skin and Skin Structure Infections Drugs Production Market Share by Application (2027-2032) Table 129. Global Complicated Skin and Skin Structure Infections Drugs Production Value by Application (2021-2026) & (US$ Million) Table 130. Global Complicated Skin and Skin Structure Infections Drugs Production Value by Application (2027-2032) & (US$ Million) Table 131. Global Complicated Skin and Skin Structure Infections Drugs Production Value Market Share by Application (2021-2026) Table 132. Global Complicated Skin and Skin Structure Infections Drugs Production Value Market Share by Application (2027-2032) Table 133. Global Complicated Skin and Skin Structure Infections Drugs Price by Application (2021-2026) & (USD/t) Table 134. Global Complicated Skin and Skin Structure Infections Drugs Price by Application (2027-2032) & (USD/t) Table 135. Key Raw Materials Table 136. Raw Materials Key Suppliers Table 137. Complicated Skin and Skin Structure Infections Drugs Distributors List Table 138. Complicated Skin and Skin Structure Infections Drugs Customers List Table 139. Complicated Skin and Skin Structure Infections Drugs Industry Trends Table 140. Complicated Skin and Skin Structure Infections Drugs Industry Drivers Table 141. Complicated Skin and Skin Structure Infections Drugs Industry Restraints Table 142. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Complicated Skin and Skin Structure Infections Drugs Product Image Figure 5. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Vancomycin Product Image Figure 7. Ceftaroline Product Image Figure 8. Tedizolid Product Image Figure 9. Tedizolid Product Image Figure 10. Linezolid Product Image Figure 11. Darbavansing Product Image Figure 12. Olivanstar Product Image Figure 13. Specialist Clinic Product Image Figure 14. Hospital Product Image Figure 15. Home Care Product Image Figure 16. Other Product Image Figure 17. Global Complicated Skin and Skin Structure Infections Drugs Production Value (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Complicated Skin and Skin Structure Infections Drugs Production Value (2021-2032) & (US$ Million) Figure 19. Global Complicated Skin and Skin Structure Infections Drugs Production Capacity (2021-2032) & (t) Figure 20. Global Complicated Skin and Skin Structure Infections Drugs Production (2021-2032) & (t) Figure 21. Global Complicated Skin and Skin Structure Infections Drugs Average Price (USD/t) & (2021-2032) Figure 22. Global Complicated Skin and Skin Structure Infections Drugs Key Manufacturers, Manufacturing Sites & Headquarters Figure 23. Global Top 5 and 10 Complicated Skin and Skin Structure Infections Drugs Players Market Share by Production Value in 2025 Figure 24. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Global Complicated Skin and Skin Structure Infections Drugs Production Comparison by Region: 2021 VS 2025 VS 2032 (t) Figure 26. Global Complicated Skin and Skin Structure Infections Drugs Production Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Complicated Skin and Skin Structure Infections Drugs Production Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Complicated Skin and Skin Structure Infections Drugs Production Value Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Complicated Skin and Skin Structure Infections Drugs Production Value (US$ Million) Growth Rate (2021-2032) Figure 30. Europe Complicated Skin and Skin Structure Infections Drugs Production Value (US$ Million) Growth Rate (2021-2032) Figure 31. China Complicated Skin and Skin Structure Infections Drugs Production Value (US$ Million) Growth Rate (2021-2032) Figure 32. Japan Complicated Skin and Skin Structure Infections Drugs Production Value (US$ Million) Growth Rate (2021-2032) Figure 33. Global Complicated Skin and Skin Structure Infections Drugs Consumption Comparison by Region: 2021 VS 2025 VS 2032 (t) Figure 34. Global Complicated Skin and Skin Structure Infections Drugs Consumption Market Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 36. North America Complicated Skin and Skin Structure Infections Drugs Consumption Market Share by Country (2021-2032) Figure 37. United States Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 38. United States Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 39. Canada Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 40. Mexico Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 41. Europe Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 42. Europe Complicated Skin and Skin Structure Infections Drugs Consumption Market Share by Country (2021-2032) Figure 43. Germany Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 44. France Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 45. U.K. Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 46. Italy Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 47. Russia Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 48. Spain Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 49. Netherlands Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 50. Switzerland Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 51. Sweden Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 52. Poland Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 53. Asia Pacific Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 54. Asia Pacific Complicated Skin and Skin Structure Infections Drugs Consumption Market Share by Country (2021-2032) Figure 55. China Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 56. Japan Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 57. South Korea Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 58. India Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 59. Australia Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 60. Taiwan Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 61. Southeast Asia Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 62. South America, Middle East & Africa Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 63. South America, Middle East & Africa Complicated Skin and Skin Structure Infections Drugs Consumption Market Share by Country (2021-2032) Figure 64. Brazil Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 65. Argentina Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 66. Chile Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 67. Turkey Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 68. GCC Countries Complicated Skin and Skin Structure Infections Drugs Consumption and Growth Rate (2021-2032) & (t) Figure 69. Global Complicated Skin and Skin Structure Infections Drugs Production Market Share by Type (2021-2032) Figure 70. Global Complicated Skin and Skin Structure Infections Drugs Production Value Market Share by Type (2021-2032) Figure 71. Global Complicated Skin and Skin Structure Infections Drugs Price (USD/t) by Type (2021-2032) Figure 72. Global Complicated Skin and Skin Structure Infections Drugs Production Market Share by Application (2021-2032) Figure 73. Global Complicated Skin and Skin Structure Infections Drugs Production Value Market Share by Application (2021-2032) Figure 74. Global Complicated Skin and Skin Structure Infections Drugs Price (USD/t) by Application (2021-2032) Figure 75. Complicated Skin and Skin Structure Infections Drugs Value Chain Figure 76. Complicated Skin and Skin Structure Infections Drugs Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Complicated Skin and Skin Structure Infections Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Vancomycin
  • Ceftaroline
  • Tedizolid
  • Tedizolid
  • Linezolid
  • Darbavansing
  • Olivanstar
Applications
  • Specialist Clinic
  • Hospital
  • Home Care
  • Other
Companies covered
  • Abbott
  • Cipla Inc
  • Dr Reddy's Laboratories Ltd
  • Endo International Inc
  • F. Hoffmann-La Roche Ltd
  • Glenmark Pharmaceuticals Ltd
  • Lupin
  • Melinta Therapeutics, Inc
  • MerLion Pharmaceuticals GmbH
  • Novartis AG
  • Paratek Pharmaceuticals, Inc
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd
  • Zydus Group

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Complicated Skin and Skin Structure Infections Drugs by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  4. 2.2.2 Vancomycin
  5. 2.2.3 Ceftaroline
  6. 2.2.4 Tedizolid
  7. 2.2.5 Tedizolid
  8. 2.2.6 Linezolid
  9. 2.2.7 Darbavansing
  10. 2.2.8 Olivanstar
  11. 2.3 Complicated Skin and Skin Structure Infections Drugs by Application
  12. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
  13. 2.3.2 Specialist Clinic
  14. 2.3.3 Hospital
  15. 2.3.4 Home Care
  16. 2.3.5 Other
  17. 2.4 Global Market Growth Prospects
  18. 2.4.1 Global Complicated Skin and Skin Structure Infections Drugs Production Value Estimates and Forecasts (2021-2032)
  19. 2.4.2 Global Complicated Skin and Skin Structure Infections Drugs Production Capacity Estimates and Forecasts (2021-2032)
  20. 2.4.3 Global Complicated Skin and Skin Structure Infections Drugs Production Estimates and Forecasts (2021-2032)
  21. 2.4.4 Global Complicated Skin and Skin Structure Infections Drugs Market Average Price (2021-2032)
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Complicated Skin and Skin Structure Infections Drugs Production by Manufacturers (2021-2026)
  2. 3.2 Global Complicated Skin and Skin Structure Infections Drugs Production Value by Manufacturers (2021-2026)
  3. 3.3 Global Complicated Skin and Skin Structure Infections Drugs Average Price by Manufacturers (2021-2026)
  4. 3.4 Global Complicated Skin and Skin Structure Infections Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Complicated Skin and Skin Structure Infections Drugs Key Manufacturers, Manufacturing Sites & Headquarters
  6. 3.6 Global Complicated Skin and Skin Structure Infections Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Complicated Skin and Skin Structure Infections Drugs Manufacturers Established Date
  8. 3.8 Global Complicated Skin and Skin Structure Infections Drugs Market CR5 and HHI
  9. 3.9 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Abbott
  2. 4.1.1 Abbott Complicated Skin and Skin Structure Infections Drugs Company Information
  3. 4.1.2 Abbott Complicated Skin and Skin Structure Infections Drugs Business Overview
  4. 4.1.3 Abbott Complicated Skin and Skin Structure Infections Drugs Production Capacity, Value and Gross Margin (2021-2026)
  5. 4.1.4 Abbott Product Portfolio
  6. 4.1.5 Abbott Recent Developments
  7. 4.2 Cipla Inc
  8. 4.2.1 Cipla Inc Complicated Skin and Skin Structure Infections Drugs Company Information
  9. 4.2.2 Cipla Inc Complicated Skin and Skin Structure Infections Drugs Business Overview
  10. 4.2.3 Cipla Inc Complicated Skin and Skin Structure Infections Drugs Production Capacity, Value and Gross Margin (2021-2026)
  11. 4.2.4 Cipla Inc Product Portfolio
  12. 4.2.5 Cipla Inc Recent Developments
  13. 4.3 Dr Reddy's Laboratories Ltd
  14. 4.3.1 Dr Reddy's Laboratories Ltd Complicated Skin and Skin Structure Infections Drugs Company Information
  15. 4.3.2 Dr Reddy's Laboratories Ltd Complicated Skin and Skin Structure Infections Drugs Business Overview
  16. 4.3.3 Dr Reddy's Laboratories Ltd Complicated Skin and Skin Structure Infections Drugs Production Capacity, Value and Gross Margin (2021-2026)
  17. 4.3.4 Dr Reddy's Laboratories Ltd Product Portfolio
  18. 4.3.5 Dr Reddy's Laboratories Ltd Recent Developments
  19. 4.4 Endo International Inc
  20. 4.4.1 Endo International Inc Complicated Skin and Skin Structure Infections Drugs Company Information
  21. 4.4.2 Endo International Inc Complicated Skin and Skin Structure Infections Drugs Business Overview
  22. 4.4.3 Endo International Inc Complicated Skin and Skin Structure Infections Drugs Production Capacity, Value and Gross Margin (2021-2026)
  23. 4.4.4 Endo International Inc Product Portfolio
  24. 4.4.5 Endo International Inc Recent Developments
  25. 4.5 F. Hoffmann-La Roche Ltd
  26. 4.5.1 F. Hoffmann-La Roche Ltd Complicated Skin and Skin Structure Infections Drugs Company Information
  27. 4.5.2 F. Hoffmann-La Roche Ltd Complicated Skin and Skin Structure Infections Drugs Business Overview
  28. 4.5.3 F. Hoffmann-La Roche Ltd Complicated Skin and Skin Structure Infections Drugs Production Capacity, Value and Gross Margin (2021-2026)
  29. 4.5.4 F. Hoffmann-La Roche Ltd Product Portfolio
  30. 4.5.5 F. Hoffmann-La Roche Ltd Recent Developments
  31. 4.6 Glenmark Pharmaceuticals Ltd
  32. 4.6.1 Glenmark Pharmaceuticals Ltd Complicated Skin and Skin Structure Infections Drugs Company Information
  33. 4.6.2 Glenmark Pharmaceuticals Ltd Complicated Skin and Skin Structure Infections Drugs Business Overview
  34. 4.6.3 Glenmark Pharmaceuticals Ltd Complicated Skin and Skin Structure Infections Drugs Production Capacity, Value and Gross Margin (2021-2026)
  35. 4.6.4 Glenmark Pharmaceuticals Ltd Product Portfolio
  36. 4.6.5 Glenmark Pharmaceuticals Ltd Recent Developments
  37. 4.7 Lupin
  38. 4.7.1 Lupin Complicated Skin and Skin Structure Infections Drugs Company Information
  39. 4.7.2 Lupin Complicated Skin and Skin Structure Infections Drugs Business Overview
  40. 4.7.3 Lupin Complicated Skin and Skin Structure Infections Drugs Production Capacity, Value and Gross Margin (2021-2026)
  41. 4.7.4 Lupin Product Portfolio
  42. 4.7.5 Lupin Recent Developments
  43. 4.8 Melinta Therapeutics, Inc
  44. 4.8.1 Melinta Therapeutics, Inc Complicated Skin and Skin Structure Infections Drugs Company Information
  45. 4.8.2 Melinta Therapeutics, Inc Complicated Skin and Skin Structure Infections Drugs Business Overview
  46. 4.8.3 Melinta Therapeutics, Inc Complicated Skin and Skin Structure Infections Drugs Production Capacity, Value and Gross Margin (2021-2026)
  47. 4.8.4 Melinta Therapeutics, Inc Product Portfolio
  48. 4.8.5 Melinta Therapeutics, Inc Recent Developments
  49. 4.9 MerLion Pharmaceuticals GmbH
  50. 4.9.1 MerLion Pharmaceuticals GmbH Complicated Skin and Skin Structure Infections Drugs Company Information
  51. 4.9.2 MerLion Pharmaceuticals GmbH Complicated Skin and Skin Structure Infections Drugs Business Overview
  52. 4.9.3 MerLion Pharmaceuticals GmbH Complicated Skin and Skin Structure Infections Drugs Production Capacity, Value and Gross Margin (2021-2026)
  53. 4.9.4 MerLion Pharmaceuticals GmbH Product Portfolio
  54. 4.9.5 MerLion Pharmaceuticals GmbH Recent Developments
  55. 4.10 Novartis AG
  56. 4.10.1 Novartis AG Complicated Skin and Skin Structure Infections Drugs Company Information
  57. 4.10.2 Novartis AG Complicated Skin and Skin Structure Infections Drugs Business Overview
  58. 4.10.3 Novartis AG Complicated Skin and Skin Structure Infections Drugs Production Capacity, Value and Gross Margin (2021-2026)
  59. 4.10.4 Novartis AG Product Portfolio
  60. 4.10.5 Novartis AG Recent Developments
  61. 4.11 Paratek Pharmaceuticals, Inc
  62. 4.11.1 Paratek Pharmaceuticals, Inc Complicated Skin and Skin Structure Infections Drugs Company Information
  63. 4.11.2 Paratek Pharmaceuticals, Inc Complicated Skin and Skin Structure Infections Drugs Business Overview
  64. 4.11.3 Paratek Pharmaceuticals, Inc Complicated Skin and Skin Structure Infections Drugs Production Capacity, Value and Gross Margin (2021-2026)
  65. 4.11.4 Paratek Pharmaceuticals, Inc Product Portfolio
  66. 4.11.5 Paratek Pharmaceuticals, Inc Recent Developments
  67. 4.12 Pfizer Inc
  68. 4.12.1 Pfizer Inc Complicated Skin and Skin Structure Infections Drugs Company Information
  69. 4.12.2 Pfizer Inc Complicated Skin and Skin Structure Infections Drugs Business Overview
  70. 4.12.3 Pfizer Inc Complicated Skin and Skin Structure Infections Drugs Production Capacity, Value and Gross Margin (2021-2026)
  71. 4.12.4 Pfizer Inc Product Portfolio
  72. 4.12.5 Pfizer Inc Recent Developments
  73. 4.13 Teva Pharmaceutical Industries Ltd
  74. 4.13.1 Teva Pharmaceutical Industries Ltd Complicated Skin and Skin Structure Infections Drugs Company Information
  75. 4.13.2 Teva Pharmaceutical Industries Ltd Complicated Skin and Skin Structure Infections Drugs Business Overview
  76. 4.13.3 Teva Pharmaceutical Industries Ltd Complicated Skin and Skin Structure Infections Drugs Production Capacity, Value and Gross Margin (2021-2026)
  77. 4.13.4 Teva Pharmaceutical Industries Ltd Product Portfolio
  78. 4.13.5 Teva Pharmaceutical Industries Ltd Recent Developments
  79. 4.14 Zydus Group
  80. 4.14.1 Zydus Group Complicated Skin and Skin Structure Infections Drugs Company Information
  81. 4.14.2 Zydus Group Complicated Skin and Skin Structure Infections Drugs Business Overview
  82. 4.14.3 Zydus Group Complicated Skin and Skin Structure Infections Drugs Production Capacity, Value and Gross Margin (2021-2026)
  83. 4.14.4 Zydus Group Product Portfolio
  84. 4.14.5 Zydus Group Recent Developments
5 Global Complicated Skin and Skin Structure Infections Drugs Production by Region
  1. 5.1 Global Complicated Skin and Skin Structure Infections Drugs Production Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Complicated Skin and Skin Structure Infections Drugs Production by Region: 2021-2032
  3. 5.2.1 Global Complicated Skin and Skin Structure Infections Drugs Production by Region: 2021-2026
  4. 5.2.2 Global Complicated Skin and Skin Structure Infections Drugs Production Forecast by Region (2027-2032)
  5. 5.3 Global Complicated Skin and Skin Structure Infections Drugs Production Value Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
  6. 5.4 Global Complicated Skin and Skin Structure Infections Drugs Production Value by Region: 2021-2032
  7. 5.4.1 Global Complicated Skin and Skin Structure Infections Drugs Production Value by Region: 2021-2026
  8. 5.4.2 Global Complicated Skin and Skin Structure Infections Drugs Production Value Forecast by Region (2027-2032)
  9. 5.5 Global Complicated Skin and Skin Structure Infections Drugs Market Price Analysis by Region (2021-2026)
  10. 5.6 Global Complicated Skin and Skin Structure Infections Drugs Production and Value, YOY Growth
  11. 5.6.1 North America Complicated Skin and Skin Structure Infections Drugs Production Value Estimates and Forecasts (2021-2032)
  12. 5.6.2 Europe Complicated Skin and Skin Structure Infections Drugs Production Value Estimates and Forecasts (2021-2032)
  13. 5.6.3 China Complicated Skin and Skin Structure Infections Drugs Production Value Estimates and Forecasts (2021-2032)
  14. 5.6.4 Japan Complicated Skin and Skin Structure Infections Drugs Production Value Estimates and Forecasts (2021-2032)
6 Global Complicated Skin and Skin Structure Infections Drugs Consumption by Region
  1. 6.1 Global Complicated Skin and Skin Structure Infections Drugs Consumption Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Complicated Skin and Skin Structure Infections Drugs Consumption by Region (2021-2032)
  3. 6.2.1 Global Complicated Skin and Skin Structure Infections Drugs Consumption by Region: 2021-2026
  4. 6.2.2 Global Complicated Skin and Skin Structure Infections Drugs Forecasted Consumption by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Complicated Skin and Skin Structure Infections Drugs Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Complicated Skin and Skin Structure Infections Drugs Consumption by Country (2021-2032)
  8. 6.3.3 United States
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Complicated Skin and Skin Structure Infections Drugs Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Complicated Skin and Skin Structure Infections Drugs Consumption by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Russia
  19. 6.4.8 Spain
  20. 6.4.9 Netherlands
  21. 6.4.10 Switzerland
  22. 6.4.11 Sweden
  23. 6.4.12 Poland
  24. 6.5 Asia Pacific
  25. 6.5.1 Asia Pacific Complicated Skin and Skin Structure Infections Drugs Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
  26. 6.5.2 Asia Pacific Complicated Skin and Skin Structure Infections Drugs Consumption by Country (2021-2032)
  27. 6.5.3 China
  28. 6.5.4 Japan
  29. 6.5.5 South Korea
  30. 6.5.6 India
  31. 6.5.7 Australia
  32. 6.5.8 Taiwan
  33. 6.5.9 Southeast Asia
  34. 6.6 South America, Middle East & Africa
  35. 6.6.1 South America, Middle East & Africa Complicated Skin and Skin Structure Infections Drugs Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
  36. 6.6.2 South America, Middle East & Africa Complicated Skin and Skin Structure Infections Drugs Consumption by Country (2021-2032)
  37. 6.6.3 Brazil
  38. 6.6.4 Argentina
  39. 6.6.5 Chile
  40. 6.6.6 Turkey
  41. 6.6.7 GCC Countries
7 Segment by Type
  1. 7.1 Global Complicated Skin and Skin Structure Infections Drugs Production by Type (2021-2032)
  2. 7.1.1 Global Complicated Skin and Skin Structure Infections Drugs Production by Type (2021-2032) & (t)
  3. 7.1.2 Global Complicated Skin and Skin Structure Infections Drugs Production Market Share by Type (2021-2032)
  4. 7.2 Global Complicated Skin and Skin Structure Infections Drugs Production Value by Type (2021-2032)
  5. 7.2.1 Global Complicated Skin and Skin Structure Infections Drugs Production Value by Type (2021-2032) & (US$ Million)
  6. 7.2.2 Global Complicated Skin and Skin Structure Infections Drugs Production Value Market Share by Type (2021-2032)
  7. 7.3 Global Complicated Skin and Skin Structure Infections Drugs Price by Type (2021-2032)
8 Segment by Application
  1. 8.1 Global Complicated Skin and Skin Structure Infections Drugs Production by Application (2021-2032)
  2. 8.1.1 Global Complicated Skin and Skin Structure Infections Drugs Production by Application (2021-2032) & (t)
  3. 8.1.2 Global Complicated Skin and Skin Structure Infections Drugs Production Market Share by Application (2021-2032)
  4. 8.2 Global Complicated Skin and Skin Structure Infections Drugs Production Value by Application (2021-2032)
  5. 8.2.1 Global Complicated Skin and Skin Structure Infections Drugs Production Value by Application (2021-2032) & (US$ Million)
  6. 8.2.2 Global Complicated Skin and Skin Structure Infections Drugs Production Value Market Share by Application (2021-2032)
  7. 8.3 Global Complicated Skin and Skin Structure Infections Drugs Price by Application (2021-2032)
9 Value Chain and Sales Channels Analysis of the Market
  1. 9.1 Complicated Skin and Skin Structure Infections Drugs Value Chain Analysis
  2. 9.1.1 Complicated Skin and Skin Structure Infections Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Complicated Skin and Skin Structure Infections Drugs Production Mode & Process
  5. 9.2 Complicated Skin and Skin Structure Infections Drugs Sales Channels Analysis
  6. 9.2.1 Direct Comparison with Distribution Share
  7. 9.2.2 Complicated Skin and Skin Structure Infections Drugs Distributors
  8. 9.2.3 Complicated Skin and Skin Structure Infections Drugs Customers
10 Global Complicated Skin and Skin Structure Infections Drugs Analyzing Market Dynamics
  1. 10.1 Complicated Skin and Skin Structure Infections Drugs Industry Trends
  2. 10.2 Complicated Skin and Skin Structure Infections Drugs Industry Drivers
  3. 10.3 Complicated Skin and Skin Structure Infections Drugs Industry Opportunities and Challenges
  4. 10.4 Complicated Skin and Skin Structure Infections Drugs Industry Restraints
11 Report Conclusion
    12 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst